Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment
Authors:
- 1 July 2006
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (7) , 924-928
Abstract
Objective: To evaluate medical and work disability costs for patients with chronic inflammatory joint disease during one year before and one year after institution of infliximab treatment in routine clinical practice. Methods: Starting from 1999, clinical and laboratory variables for patients treated with biological agents for inflammatory rheumatic diseases were systematically recorded at Helsinki University Central Hospital. From this database clinical information was collected on 96 patients in whom infliximab was started during the period 1999 to 2001. Economic analyses were based on costs incurred because of outpatient and inpatient visits, orthopaedic operations, drugs used, and days on sickness or rehabilitation allowance. Medical and work disability costs were calculated separately for the one year period before (period I) and the one year period after institution of infliximab (period II). Results: Of the study group of 96 patients (arthritis duration 16 years (range 3 to 43)), 74 completed one year of infliximab treatment. Their clinical and laboratory variables improved significantly. The mean increase in medical costs during period II was €12 015 (95% confidence interval, 6496 to 18 076). A minimal decrease in work disability costs occurred—mean decrease €130 (−1268 to 1072). Conclusions: One year treatment with infliximab in patients with longstanding aggressive arthritis showed a good clinical effect but raised medical costs significantly. Work disability costs failed to show a substantial decrease. Starting infliximab in the earlier stages of chronic arthritis could in the long term prevent work disability and thus decrease the total cost to society.Keywords
This publication has 14 references indexed in Scilit:
- Modeling the 5‐year cost effectiveness of treatment strategies including tumor necrosis factor‐blocking agents and leflunomide for treating rheumatoid arthritis in the NetherlandsArthritis Care & Research, 2004
- Overview of work disability in rheumatoid arthritis patients as observed in cross‐sectional and longitudinal surveysArthritis Care & Research, 2004
- Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexateArthritis & Rheumatism, 2004
- The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative studyAnnals of the Rheumatic Diseases, 2004
- Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label studyAnnals of the Rheumatic Diseases, 2003
- The cost‐effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT studyRheumatology, 2003
- Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritisThe American Journal of Medicine, 2002
- Etanercept in the treatment of adult patients with Still's diseaseArthritis & Rheumatism, 2002
- Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow upAnnals of the Rheumatic Diseases, 2002
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000